2021 Report on Blepharitis Drugs In Development

2021 Report on Blepharitis Drugs In Development

[ad_1]

DUBLIN, August 31, 2021–(BUSINESS WIRE)–The “Blepharitis (Ophthalmology) – Drugs In Development, 2021” report has been added to ResearchAndMarkets.com’s offering.

This report provides an overview of the Blepharitis (Ophthalmology) pipeline landscape.

Blepharitis is an inflammation of the eyelids, usually caused by an excess growth of bacteria that is ordinarily found on the skin, blockage of the eyelid’s oil glands, and occasionally allergies. Blepharitis signs and symptoms include watery eyes, red eyes, itchy eyelids, sensitivity to light. Treatment includes antibiotics, lubricating eye drops and steroid eye drops or ointments.

Report Highlights

The report provides comprehensive information on the therapeutics under development for Blepharitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

It also reviews of key players involved in therapeutic development for Blepharitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 1, 7 and 2 respectively.

Blepharitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Blepharitis (Ophthalmology).

  • The pipeline guide reviews pipeline therapeutics for Blepharitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

  • The pipeline guide reviews key companies involved in Blepharitis (Ophthalmology) therapeutics and enlists all their major and minor projects.

  • The pipeline guide evaluates Blepharitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

  • The pipeline guide reviews latest news related to pipeline therapeutics for Blepharitis (Ophthalmology)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Blepharitis (Ophthalmology).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Blepharitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned

  • Aerie Pharmaceuticals Inc

  • Aperta Biosciences LLC

  • AxeroVision Inc

  • Azura Ophthalmics Ltd

  • Formosa Pharmaceuticals Inc

  • Hovione FarmaCiencia SA

  • Merck & Co Inc

  • NicOx SA

  • Novaliq GmbH

  • NTC srl

  • Premark Pharma GmbH

  • Quorum Innovations LLC

  • Sol-Gel Technologies Ltd

  • Tarsus Pharmaceuticals Inc

For more information about this report visit https://www.researchandmarkets.com/r/mtfbqa

View source version on businesswire.com: https://www.businesswire.com/news/home/20210831005513/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

[ad_2]

Source link